Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone610-225-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.45 billion
Profitability
Miscellaneous
Employees15,200
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Teleflex (NYSE:TFX) Frequently Asked Questions
What is Teleflex's stock symbol?
Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."
How often does Teleflex pay dividends? What is the dividend yield for Teleflex?
Teleflex announced a quarterly dividend on Monday, May 6th. Investors of record on Wednesday, May 15th will be paid a dividend of $0.34 per share on Friday, June 14th. This represents a $1.36 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Tuesday, May 14th. View Teleflex's Dividend History.
How were Teleflex's earnings last quarter?
Teleflex Incorporated (NYSE:TFX) announced its quarterly earnings data on Thursday, May, 2nd. The medical technology company reported $2.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.17 by $0.07. The medical technology company had revenue of $613.60 million for the quarter, compared to analysts' expectations of $608.27 million. Teleflex had a return on equity of 18.62% and a net margin of 7.50%. The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.15 earnings per share. View Teleflex's Earnings History.
When is Teleflex's next earnings date?
What guidance has Teleflex issued on next quarter's earnings?
Teleflex updated its FY19 earnings guidance on Thursday, May, 2nd. The company provided EPS guidance of $10.90-11.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.03. Teleflex also updated its FY 2019 guidance to $10.90-11.10 EPS.
What price target have analysts set for TFX?
7 equities research analysts have issued 12-month price targets for Teleflex's shares. Their forecasts range from $309.00 to $350.00. On average, they expect Teleflex's stock price to reach $324.8571 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price. View Analyst Price Targets for Teleflex.
What is the consensus analysts' recommendation for Teleflex?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teleflex.
What are Wall Street analysts saying about Teleflex stock?
Here are some recent quotes from research analysts about Teleflex stock:
- 1. According to Zacks Investment Research, "Teleflex exited the first quarter of 2019 on a solid note with better-than-expected earnings and revenues figures. The promising performance was driven by strong growth in Interventional Urology, Interventional Access and OEM. Geographically, Asia and Americas both registered strong constant currency revenue growth. We currently look forward to Urolift’s impending limited launch Japan following its Shonn approval. This apart, Teleflex announced a major reimbursement milestone for Urolift of receiving a positive coverage decision from health insurer Humana. Vascular solutions synergy is progressing well. Management also seems to be confident about its recently completed Essential Medical buyout. On the flip side, escalating operating expenses are putting pressure on the bottom line. Tough competition and pricing pressure also weigh on the stock. Overall, in the past three months, shares of Teleflex consistently outperformed its industry." (5/14/2019)
- 2. Needham & Company LLC analysts commented, "TFX is changing its product categories and segments and we have updated our revenue model to reflect the changes. While we are maintaining our prior total revenue and EPS estimates, we are publishing our estimates for the new product categories and segments. We view RePlas as potential sources of upside to TFX’s 2019 guidance and we reiterate our Strong Buy rating." (3/26/2019)
Has Teleflex been receiving favorable news coverage?
Media headlines about TFX stock have been trending positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teleflex earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave press coverage about the medical technology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Teleflex's key competitors?
Some companies that are related to Teleflex include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Novocure (NVCR), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED) and Tandem Diabetes Care (TNDM).
What other stocks do shareholders of Teleflex own?
Who are Teleflex's key executives?
Teleflex's management team includes the folowing people:
- Mr. Liam J. Kelly, Pres, CEO & Director (Age 52)
- Mr. Thomas E. Powell, Exec. VP & CFO (Age 57)
- Mr. James J. Leyden, VP, Gen. Counsel & Sec. (Age 52)
- Mr. John R. Deren, VP & Chief Accounting Officer
- Mr. Timothy F. Duffy, Chief Information Officer & VP
Who are Teleflex's major shareholders?
Teleflex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.20%), Wellington Management Group LLP (3.42%), FMR LLC (2.92%), Select Equity Group L.P. (2.10%), Janus Henderson Group PLC (2.09%) and American Century Companies Inc. (1.85%). Company insiders that own Teleflex stock include Andrew A Krakauer, Benson Smith, Cameron P Hicks, George Babich Jr, Gretchen R Haggerty, John C Heinmiller, John Deren, Stephen K MD Klasko, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Institutional Ownership Trends for Teleflex.
Which major investors are selling Teleflex stock?
TFX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Select Equity Group L.P., Principal Financial Group Inc., Wellington Management Group LLP, Goldman Sachs Group Inc., Retirement Systems of Alabama, American International Group Inc. and American Century Companies Inc.. Company insiders that have sold Teleflex company stock in the last year include Benson Smith, Cameron P Hicks, John Deren, Stephen K MD Klasko, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Insider Buying and Selling for Teleflex.
Which major investors are buying Teleflex stock?
TFX stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Janus Henderson Group PLC, First Trust Advisors LP, Marshall Wace North America L.P., Pennsylvania Trust Co, Charles Schwab Investment Management Inc., Northern Trust Corp and Parametric Portfolio Associates LLC. Company insiders that have bought Teleflex stock in the last two years include Andrew A Krakauer, Gretchen R Haggerty and John C Heinmiller. View Insider Buying and Selling for Teleflex.
How do I buy shares of Teleflex?
Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teleflex's stock price today?
One share of TFX stock can currently be purchased for approximately $297.75.
How big of a company is Teleflex?
Teleflex has a market capitalization of $13.74 billion and generates $2.45 billion in revenue each year. The medical technology company earns $200.80 million in net income (profit) each year or $9.90 on an earnings per share basis. Teleflex employs 15,200 workers across the globe.
What is Teleflex's official website?
How can I contact Teleflex?
Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected]
MarketBeat Community Rating for Teleflex (NYSE TFX)
MarketBeat's community ratings are surveys of what our community members think about Teleflex and other stocks. Vote "Outperform" if you believe TFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TFX will underperform the S&P 500 over the long term. You may vote once every thirty days.
